NCT00145886TERMINATEDanonymous

Effect of 12 Months Treatment With rhPTH on Calcium Balance, Bone Turnover, Bone Mineral Density, and Bone Micro-architecture in Patients With Fractures Associated With Low Bone Turnover and Sclerosing Bone Disorders

Sponsor

Source record

University of Chicago

Phase

Source record

PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

rhPTH

Indication / condition

AI-normalized

Osteopetrosis

Intervention

Source record

rhPTH

Related intelligence directories

Indication directory: Osteopetrosis Modality directory: small molecule Target directory: rhPTH

Source & freshness

Source record

NCT ID

NCT00145886

Original source

ClinicalTrials.gov

Source last updated

Jan 12, 2016

Ingested at

Jun 19, 2026

Internal sync

Jun 19, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT00145886

Title

Effect of 12 Months Treatment With rhPTH on Calcium Balance, Bone Turnover, Bone Mineral Density, and Bone Micro-architecture in Patients With Fractures Associated With Low Bone Turnover and Sclerosing Bone Disorders

Sponsor

University of Chicago

Status

TERMINATED

Phase

PHASE1

Condition raw

Osteopetrosis

Condition normalized

Osteopetrosis

Modality raw

small molecule

Modality normalized

small molecule

Target raw

rhPTH

Target normalized

rhPTH

Interventions

rhPTH

Public preview

Source record

The purpose of this study is to determine how treatment with a new medication, recombinant human parathyroid hormone (rhPTH) affects calcium balance and bone strength.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Effect of 12 Months Treatment With rhPTH on Calcium Balance, Bone Turnover, Bone Mineral Density, and Bone Micro-architecture in Patients With Fractures Associated With Low Bone Turnover and Sclerosing Bone Disorders

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT00145886

Status

TERMINATED

Phase

PHASE1

Sponsor

University of Chicago

Executive brief

Investment-Ready Snapshot

The purpose of this study is to determine how treatment with a new medication, recombinant human parathyroid hormone (rhPTH) affects calcium balance and bone strength.

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedJan 12, 2016

Internal syncJun 19, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00145886

Indication

Osteopetrosis

Modality

small molecule

Target

rhPTH

Intervention

rhPTH

Source record